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Abstract
Background
To validate the point of care testing (POCT) Trop-I analyzer and compare it with a central
laboratory-based chemiluminescence immunoassay, in order to evaluate its performance for
use in critical care areas. Moreover, for clinical decision-making, it is imperative to know the
extent to which patient stratification will differ based on the analytic method being used. In
particular, the aim of this study was to evaluate the analytical performance of the point-of-care
analyzer and demonstrate the agreement with the central laboratory measurements in patients
presenting to the emergency department (ED) with chest pain and suspected acute coronary
syndrome (ACS).
Methods
This cross-sectional study was performed at the section of chemical pathology, department of
pathology and laboratory medicine, the Aga Khan University (AKU), Karachi, from October to
November 2017. Samples from patients and the quality control material of Trop-I were analyzed
for imprecision, linearity, and method comparison on Advia Centaur (Siemens Diagnostics, CA,
USA), and the AQT90 FLEX analyzer (Radiometer Medical ApS, Brønshøj, Denmark) with
photometric detection at the section of chemical pathology, AKU. Statistical analysis was done
using Microsoft Excel (Microsoft Corporation, Washington, United States) and EP Evaluator
version 10.3.0.556 (Data Innovations, LLC, VT, US). Quantitative variables were represented in
terms of mean ± SD. For precision, the computed SD was compared with allowable random
error. Furthermore, Cohen’s kappa was applied to observe the agreement between the two
methods.
Results
The Trop-I Precision study on the POCT analyzer showed a coefficient of variation (CV) of 2.4%
using a pooled patient sample with a mean Trop-I of 2.15 ± 0.05 ng/ml. Three standards ranging
from 0.034 to 1.316 ng/ml were run in triplicate to verify accuracy and linearity. The allowable
systematic error (SEa) was 10.0%. The maximum deviation for a mean recovery from 100% was
4.1%. All three of the mean recoveries were accurate and within the allowable error limits. The
results were linear with slope 1.04, intercept 0.0. On a method comparison, Trop-I showed good
agreement, yielding a kappa value of 0.95.
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Conclusion
This study has validated the performance of a POCT Trop-I assay against a central laboratory
immunoassay and found acceptable results. POCT assays for cTnI should be implanted in
emergency settings to ensure the fast triage of patients with chest pain, as well as timely
diagnosis.
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Introduction
The rapid diagnosis of acute coronary syndrome (ACS) relies pivotally on cardiac troponin (cTn)
assays [1]. From a laboratorian’s perspective, cTn has been widely accepted as the leading
biochemical marker of myocardial injury owing to its exclusive synthesis in the myocardium
[2]. As per the recommendations of the American College of Cardiology, the results of cTn
should be ideally available within 30 to 60 minutes of patient presentation into critical care
areas [3]. However, an evaluation of worldwide practices shows that most of the central hospital
laboratories find it difficult to comply with these guidelines of the rapid availability of cTn
results for optimum patient management [4].
The possible solution to meet the optimum turnaround times for cTn, especially in emergency
settings, is bedside point-of-care systems [5]. The POCT devices offer potential benefits,
ranging from the prevention of delays in sample transportation and processing in a central
laboratory, and further eradicates interruptions caused by the non-availability of central
laboratories for various clinical setups [6].
On the contrary, POCT has certain limitations as well as necessitates rigorous quality control
and adequate training of emergency department (ED) end users [7]. Various studies have
reported extensive alarms regarding the potentially decreased accuracy of bedside analyzers
and have revealed the impact of false negative and false positive results on patient
management, unjustified expenditure, and test requests [8-9]. Discordances defined as one
method reading at more than the 99th percentile limit and the comparator less than the limit
between the cTn-I values among different POCT assays and central laboratory assays have been
reported [10-11].
The clinical laboratory, as a standards institute, recommends that laboratories should validate
and evaluate the performance of POCT devices with pre-validated central laboratory-based
assays to meet acceptable performance standards [12]. Moreover, for clinical decision-making,
it is imperative to know the extent to which patient stratification will differ based on the
analytic method being used.
In this study, we evaluated two different cTn-I assays, one POCT (AQT90 FLEX, Radiometer
Medical ApS, Brønshøj, Denmark) and one used in emergency and routine situations at our
laboratory (Advia Centaur, Siemens Diagnostics, CA, USA). In particular, the aim of this study
was to evaluate the analytical performance of the point-of-care analyzer and demonstrate the
agreement with the central laboratory measurements in patients presenting to the emergency
department (ED) with chest pain and suspected ACS.
Materials And Methods
This study was conducted at the section of chemical pathology, department of pathology and
laboratory medicine, the Aga Khan University Hospital, Karachi, from October to November
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2017. The section of chemical pathology in the central laboratory caters to the emergency
department of one of the largest and extensive private sector hospitals in the region.
The cTn-I is analyzed in the central laboratory on the Siemens Adiva Centaur platform. The
system was monitored by routine internal quality control procedures per the Clinical and
Laboratory Standards Institute (CLSI) standards and participation in College of American
Pathologists (CAP) external quality assurance surveys.
Forty de-identified patient samples with cTn-I levels in the range of 0.006 to 50 ng/ml
measured on the Siemens Advia centaur chemiluminescence immunoassay collected in the
course of routine patient care presenting at the ED with chest pain and ischemic symptoms to
rule in or rule out ACS were subjected to testing on the POCT Radiometer AQT90 FLEX
analyzer. As the study was non-interventional, informed consent from the participants was not
required. Additionally, three standards as provided by the manufacturer were also used to verify
the precision accuracy and linearity of cTn-I testing on both analyzers. The diagnostic cutoff
for acute coronary syndrome was taken as >0.04 ng/ml for the Advia Centaur and >0.023 ng/ml
for the AQT 90 Flex analyzer as recommended by the manufacturer's package insert.
Statistical analysis was done using EP Evaluator version 10.3.0.556 (Data Innovations, LLC, VT,
US). Quantitative variables were represented in terms of mean ± SD. For precision, the
computed SD was compared with an allowable random error. Furthermore, Cohen’s kappa was
applied to observe the agreement between the two methods.
Results
A total of 40 samples measured on the Siemens Advia Centaur chemiluminescence
immunoassay in routine clinical care cTn-I levels were subjected to a re-analysis on the POCT
Radiometer AQT90 FLEX analyzer. It was ensured that the cTn-I samples used for the study
covered the entire analytical measurement range from 0.006 to 50 ng/ml. Nineteen (47.5%) of
the samples had cTn-I above the cut off (>0.04 ng/ml).
For precision, 20 samples were analyzed in duplicate on the POCT analyzer and the results were
inserted into the EP evaluator, which generated a coefficient of variation (CV) of 2.4% with
mean cTn-I of 2.15 ± 0.05 ng/ml. The precision study was acceptable as the computed standard
deviation of 0.05 did not exceed the allowable random error of 2.5%, as shown in Figure 1.
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FIGURE 1: Precision plot for cTn-I analyzed by the AQT90 FLEX
analyzer
Precision plot
AQT90 FLEX analyzer: Radiometer Medical ApS, Brønshøj, Denmark
Three standards ranging from 0.034 to 1.316 ng/ml were run in triplicate to verify accuracy and
linearity for the AQT 90 FLEX analyzer. The accuracy test was acceptable as the Allowable
Systematic error (SEa) was 10.0%. The maximum deviation for a mean recovery from 100% was
4.1%. Three of three mean recoveries were accurate and within the allowable error limits.
Furthermore, the results were linear with a slope of 1.04 and intercept 0.0, as demonstrated in
Figures 2-3.
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FIGURE 2: Accuracy plot for cTn-I analyzed by the AQT90 FLEX
analyzer
Scatter plot
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FIGURE 3: Percent recovery for cTn-I analyzed by the AQT90
FLEX analyzer
Percent recovery
AQT90 FLEX analyzer: Radiometer Medical ApS, Brønshøj, Denmark
For a method comparison between the POCT and central laboratory analyzer, 40 de-identified
patient samples re-analyzed on the AQT90 Flex analyzer revealed a good agreement yielding a
kappa value of 0.95, as shown in Table 1.
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 Statistical Summary  
 Negative Reference Positive Reference Total Kappa value
Negative Reference 21(52.5%) 1(2.5%) 22(55%)
0.95Positive Reference 0(0%) 18(45%) 18(45%)
Total 21(52.5%) 19(47.5%) 40(100%)
TABLE 1: Agreement between AQT 90 FLEX and Advia Centaur cTn-I
AQT90 FLEX analyzer: Radiometer Medical ApS, Brønshøj, Denmark; Advia Centaur: Siemens Diagnostics, CA, USA
 
Discussion
To the best of our knowledge, this is the first study from Pakistan to evaluate the POCT
performance of cTn-I. A significant element in determining the clinical utility of POCT cTn
testing is the diagnostic performance of an assay at admission, as compared to a central
laboratory assay, to rapidly rule out ACS. Moreover, the importance increases several thousand
folds for ED clinical care providers in order to ensure appropriate triage and patient
management with the critical goal of improving patient outcomes [13-15].
In 2001, the International Federation of Clinical Chemistry (IFCC) recommended that
manufacturers have a target of <10% CV at the myocardial infarction decision limit [16]. A
previously undertaken study by Meon et al. and Herbert et al. in a similar setting has reported
the acceptable precision of the AQT 90 Flex analyzer considering the stringent <10% CV goal.
The results of this study with a CV of 2.4% with mean cTn-I of 2.15 ± 0.05 ng/ml are in
concordance with the literature [17-18]. Furthermore, the assay demonstrated acceptable
linearity covering a range from 0.034 to 1.316 ng/ml to ensure a reliable clinical utility to rule
out or rule in ACS.
For the determination of the clinical utility of POCT cTn-I, 40 patient samples analyzed on the
two comparative platforms revealed an agreement of 95%, which is in concordance with other
reported literature [19]. Apart from ACS, cTn-I can be elevated in certain non-cardiac
pathologies as well as including renal failure [20-21]. In this study, the one patient with a
discordant result had chronic renal failure that compromised the performance of the bedside
analyzer with a lower cut-off for the diagnosis of ACS compared to Advia Centaur.
The current study has a few limitations. First, the sample size was small, limiting the power of
the study and there is a likelihood that the significant variation in findings may arise with
larger sample size. Second, this study was not undertaken to associate the utilized cutoffs with
clinical diagnosis. Future studies are required in resource-limited set-ups like ours to assess the
suitability of POCT testing in clinical settings (e.g., emergency department for strategies to rule
in or rule out acute myocardial infarction (AMI)) and cost-effectiveness of standardizing the
cTnI cutoffs between POCT and central laboratory assays.
Conclusions
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This study has validated the performance of a POCT Trop-I assay against a central laboratory
immunoassay and found acceptable results. POCT assays for cTnI should be implanted in
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